OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Leventakos on Remaining Questions After PACIFIC Trial in Lung Cancer

August 27th 2019

Konstantinos Leventakos, MD, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer treatment, as well as what questions still remain.

Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

August 27th 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Dr. Cowan on the Future of Selinexor in Multiple Myeloma

August 23rd 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington School of Medicine, and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the future of selinexor (Xpovio) in multiple myeloma.

Dr. Martin on Provider Confidence With Biosimilars in Oncology

August 23rd 2019

Miguel Martín, MD, PhD, professor of medicine at the Complutense University, and head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon in Madrid, Spain, discusses provider confidence with biosimilars in oncology.

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

August 23rd 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Esteva on the Future of Biosimilars in Breast Cancer

August 23rd 2019

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States.

Dr. Schiller on the Importance of Genomic Testing in AML

August 23rd 2019

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia.

Dr. Philip on Adverse Events With Lutathera in NETs

August 23rd 2019

Philip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).

Dr. Hurvitz on the Potential Global Impact of Biosimilars in Breast Cancer

August 23rd 2019

Sara Hurvitz, MD, associate professor, David Geffen School of Medicine, UCLA; medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; and director, Breast Cancer Clinical Trials Program, UCLA, discusses the potential global impact of biosimilars in breast cancer.

Dr. Joseph on the Combination of Atezolizumab and Bevacizumab in mRCC

August 23rd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).

Dr. Moore on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

August 22nd 2019

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, poses unanswered questions pertaining to the use and reuse of PARP inhibitors in ovarian cancer treatment.

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

August 22nd 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses data from a phase I trial exploring the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma.

Dr. Henderson on Proton Therapy Versus IMRT in Prostate Cancer

August 22nd 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Dr. Rossetti on Risk Stratification in Myeloproliferative Neoplasms

August 20th 2019

James M. Rossetti, DO, hematologist, UPMC Hillman Cancer Center, discusses risk stratification in myeloproliferative neoplasms (MPNs).

Dr. Lee on Data Regarding HIPEC in mCRC

August 20th 2019

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate clinical professor of surgical oncology, Department of Surgery, and surgical oncologist, City of Hope, discusses data regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with metastatic colorectal cancer (mCRC).

Dr. Schmid on the Role of Biosimilars in Oncology

August 20th 2019

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the role of biosimilars in oncology.

Dr. Davis on the Role of Ramucirumab in Gastric/GEJ Cancer

August 20th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the role of ramucirumab (Cyramza) in the treatment of patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Shadman on the Efficacy of Venetoclax in CLL

August 20th 2019

Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the efficacy of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

August 20th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Dr. Henderson on the Benefits of Proton Therapy in Prostate Cancer

August 16th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.